The first direct demonstration of IGF2R in tumor growth came from the work of Chen et al., in which they described how the downregulation of M6P/IGF2R expression in adenocarcinoma cells led to increased cell proliferation and decreased susceptibility to apoptosis, according to the bioavailability of TNFα and activated TGF-β. This evidence concerns the gene IGF2R and neoplasm.